Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SOFIVA GENOMICS Co's annualized net income for the quarter that ended in Dec. 2025 was NT$-18.1 Mil. SOFIVA GENOMICS Co's average shareholder tangible equity for the quarter that ended in Dec. 2025 was NT$624.2 Mil. Therefore, SOFIVA GENOMICS Co's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was -2.91%.
The historical rank and industry rank for SOFIVA GENOMICS Co's Return-on-Tangible-Equity or its related term are showing as below:
ROCO:6615'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.49 Med: 8.34 Max: 20.07
Current: -1.49
During the past 13 years, SOFIVA GENOMICS Co's highest Return-on-Tangible-Equity was 20.07%. The lowest was -1.49%. And the median was 8.34%.
ROCO:6615's Return-on-Tangible-Equity is ranked worse than 52.36% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.33
vs ROCO:6615: -1.49
SOFIVA GENOMICS Co (ROCO:6615) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SOFIVA GENOMICS Co Return-on-Tangible-Equity Related Terms
SOFIVA GENOMICS Co Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOFIVA GENOMICS Co Return-on-Tangible-Equity Chart
ROCO:6615 vs TMO, DHR, IDXX: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -2.91% mean?
SOFIVA GENOMICS Co (ROCO:6615) has a Return-on-Tangible-Equity of -2.91% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SOFIVA GENOMICS Co and its competitors. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #100 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 52.4%.
Is SOFIVA GENOMICS Co's Return-on-Tangible-Equity too high?
SOFIVA GENOMICS Co's current Return-on-Tangible-Equity is -2.91%. Based on the distribution chart, SOFIVA GENOMICS Co ranks #100 out of 191 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Return-on-Tangible-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #100 out of 191 companies for Return-on-Tangible-Equity. This places SOFIVA GENOMICS Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SOFIVA GENOMICS Co and its competitors. SOFIVA GENOMICS Co's current Return-on-Tangible-Equity is -2.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.90, compared to a current price of NT$33.60 — trading 8.7% above its estimated fair value. The current Return-on-Tangible-Equity is -2.91%. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Return-on-Tangible-Equity is -2.91% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$33.60 is trading 8.7% above its estimated GF Value™ of NT$30.90.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
Return-on-Tangible-Equity: -2.91%
GF Value™: NT$30.90 vs. price of NT$33.60 (8.7% above fair value)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
